A federal report found that an organ procurement organization ignored signs of life in patients when authorizing attempted ...

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...

Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the market, a senior FDA official told STAT.

New AI chatbot called Ash is different, Slingshot founders say, because its training model is based on real therapeutic ...

The number of basic science papers published by NIH grant recipients has been falling since 2013, when the agency’s budget ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...